Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
E2/NETA · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Relugolix | EXPERIMENTAL | Participants received relugolix 40 milligrams (mg) alone for 6 weeks. |
| Relugolix + E2/NETA | EXPERIMENTAL | Participants received relugolix 40 mg and E2/NETA at 1 mg/ 0.5 mg for 6 weeks. |
| Name | Type | Description |
|---|---|---|
| Relugolix | DRUG | Administered as an oral tablet once daily. |
| E2/NETA | DRUG | Administered as an oral tablet once daily. |
Inclusion Criteria: 1. Pre-menopausal female between 18 and 48 years of age. 2. E2, P, LH and FSH concentrations within 0.5x of the lower limits of normal range and 2x of the upper limits of normal upper limits of normal range (ULN) 3. Regular menstrual periods for the 3 months prior to study enrol...
E2/NETA is an investigational small molecule therapeutic being developed by Roivant Sciences Ltd. (ticker: ROIV). It has completed a Phase 1 clinical trial in healthy premenopausal female participants. The specific indications for which E2/NETA is being developed have not been disclosed.
E2/NETA is being developed by Roivant Sciences Ltd., which trades under the ticker symbol ROIV. The company has completed a Phase 1 trial of the drug.
E2/NETA is in Phase 1 of clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The drug has not been approved by the FDA and remains investigational.
E2/NETA has been evaluated in one completed Phase 1 trial, NCT04978688, titled "Study of Relugolix Alone and Relugolix Combined With Hormonal Add-Back Therapy in Healthy Premenopausal Female Participants." The trial enrolled 48 healthy premenopausal female participants in the United States and was controlled and randomized.
No, E2/NETA is not FDA approved. It is an investigational small molecule in Phase 1 clinical development, with one completed Phase 1 trial. Approval status has not been granted for any indication.